Clare Arnott's Publications

About Clare Arnott's Publications

Global Director, Cardiovascular Program
  • Co-Director, Global Chronic & Complex Diseases
  • BMed Sci,
  • MBBS (Hons),
  • PhD,
  • FRACP,
  • FESC,
  • CF

  • Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

    Journal of the American Heart Association Date published:

  • “It's like a forgotten issue sometimes …”: Qualitative study of individuals living and caring for people with chronic breathlessness

    The Clinical Respiratory Journal Date published:

  • Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering

    BMJ Open Diabetes Research & Care Date published:

  • Good for your heart and safe for your toes: a patient-level meta-analysis of DAPA-HF and DELIVER

    European Heart Journal Date published:

  • Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials

    Diabetes, Obesity and Metabolism Date published:

  • The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials

    Diabetes, Obesity and Metabolism Date published:

  • Acceptability and Feasibility of a Chronic Breathlessness Clinical Algorithm in Australian Primary Care

    C36. HIGHLIGHTS IN BEHAVIORAL SCIENCES AND HEALTH SERVICES RESEARCH Date published:

  • Chronic Breathlessness Management in Primary Care: Current Gaps and Practical Solutions

    D22. HOT TOPICS IN BEHAVIORAL SCIENCES AND HEALTH SERVICES RESEARCH Date published:

  • Associations of Breast Arterial Calcifications with Cardiovascular Disease

    Journal of Women's Health Date published:

  • Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE

    Diabetes, Obesity and Metabolism Date published:

  • Reassurance for parents with children bornvia assisted reproductive technology or too soon to tell?

    European Heart Journal Date published:

  • The importance of targeting multiple risk markers in patients with type 2 diabetes: A post-hoc study from the CANVAS programme

    Diabetes, Obesity and Metabolism Date published:

  • Contemporary Chest Pain Evaluation: The Australian Case for Cardiac CT

    Heart, Lung and Circulation Date published:

  • Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Management of chronic breathlessness in primary care: what do GPs, non-GP specialists, and allied health professionals think?

    Australian Journal of Primary Health Date published: